A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center

Aseeri, Mohammed; Mukhtar, Amnah; Khansa, Sara; Elimam, Nagla; Jastaniah, Wasil

doi:10.1177/1078155212457966

Cited by 9 publications

(6 citation statements)

References 15 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All antiemetic regimens that were ineffective to prevent CINV were found to be inconsistent with the standard guidelines. 18 …”

Section: Discussionmentioning

confidence: 99%

“…All antiemetic regimens that were ineffective to prevent CINV were found to be inconsistent with the standard guidelines. 18 The under-utilization of aprepitant, an FDA-approved agent, is an important issue. Aprepitant is recommended to be used with 5-HT3 receptor antagonists in all three reference guidelines for CINV prophylaxis for high emetogenic chemotherapy protocol.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A retrospective review of treatment patterns of antiemetic agents for chemotherapy-induced nausea and vomiting

et al. 2018

View full text Add to dashboard Cite

Objectives:To evaluate the treatment pattern of antiemetic agents used for chemotherapy-induced nausea and vomiting in a tertiary hospital in Saudi Arabia.Methods:Over a period of 7 weeks, all new chemotherapy order sheets were collected and evaluated for chemotherapy-induced nausea and vomiting management. We compared each antiemetic regimen used for chemotherapy-induced nausea and vomiting prophylaxis with three international antiemetic guidelines by the following organizations: the Multinational Association of Supportive Care in Cancer, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network for the clinician.Results:A total of 152 cancer patients were included in the study, for whom 289 chemotherapy physician orders included antiemetic regimens. Approximately 17.3% of the chemotherapy protocols had total minimal emetogenicity risk, 22.5% had low risk, 37.02% had moderate risk, and 23.18% had high risk. For acute emesis, 27.57% of the antiemetic regimens followed at least one of the three reference guidelines. For delayed emesis, only 20.16% of the antiemetic regimens adhered to at least one of the three reference guidelines.Conclusion:Adherence to treatment recommendations and antiemetics prescribing for chemotherapy-induced nausea and vomiting was suboptimal at this hospital. However, institutional antiemetic guidelines and oncology pharmacists could play an important role in better assessment and management of chemotherapy-induced nausea and vomiting.

show abstract

“…All antiemetic regimens that were ineffective to prevent CINV were found to be inconsistent with the standard guidelines. 18 …”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A retrospective review of treatment patterns of antiemetic agents for chemotherapy-induced nausea and vomiting

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In a study conducted in the Albert Einstein Israeli Hospital, in which the ASCO Guideline 10 was used, low compliance with the protocol used (22%) 11 was also found. In the global literature, the overall adherence rate of antiemetic prescriptions to the national or international antiemetic guidelines has varied from 20% to 61.9% [12][13][14][15][16][17] .…”

Section: Discussionmentioning

confidence: 99%

Evaluation of pre-chemotherapy antiemetic prescriptions in a hospital unit

Souza¹,

Cordeiro²

2020

Rev Bras Farm Hosp Serv Saude

View full text Add to dashboard Cite

Introduction: Antineoplastic drugs, due to their high toxicity, can lead to adverse reactions to drugs, such as emesis, which causes discomfort to the patient. These drugs can be classified according to emetogenic potential and have appropriate treatment protocols. Objectives: The aim of this study is to evaluate whether there is compliance between antiemetic prescription in patients receiving antineoplastic treatment in a hospital unit, according to pre-established emesis prevention protocols. Methods: This is a cross-sectional retrospective study of chemotherapy prescriptions analysis from January to April 2017. Data were analyzed according to the National Comprehensive Cancer Network 2017 Acute Emesis Prevention Protocol. Nonconformities were classified in: wrong medicine; wrong dose; wrong administration frequency and wrong administration route. Results: Of the 919 prescriptions analyzed, 83% did not comply with the protocol. The most common nonconformity found in the study was the wrong dose with the most prevalent scenario being the dexamethasone dose above the required dose. Conclusion: Most of the prescriptions analyzed did not comply with the pre-established protocol. This increases the likelihood of adverse drug reactions, does not effectively prevent emesis, thereby increasing patient weakness, decreasing quality of life, and wasting resources.

show abstract

“… 1 It has a detrimental effect on the quality of life of patients and their functional well-being. 2 - 4 Uncontrolled nausea or vomiting is also associated with frequent hospital and emergency department visits, is resource consuming, 5 - 8 and can lead to impaired compliance with chemotherapy. 1 , 9 , 10…”

Section: Introductionmentioning

confidence: 99%

Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline

Patil

Noronha²,

Joshi

et al. 2017

JGO

View full text Add to dashboard Cite

PurposeAdherence to international antiemetic prophylaxis guidelines like those of ASCO can result in better control of chemotherapy-induced nausea and vomiting; however, the extent of implementation of such guidelines in India is unknown. Therefore, this survey was planned.MethodsThis study was an anonymized cross-sectional survey approved by the ethics committee. Survey items were generated from the clinical questions given in the ASCO guidelines. The survey was disseminated through personal contacts at an oncology conference and via e-mail to various community oncology centers across India. The B1, B2, and B3 domains included questions regarding the optimal antiemetic prophylaxis for high, moderate, and low-minimal emetogenic regimens.ResultsSixty-six (62.9%) of 105 responded and 65 centers (98.5%) were aware of the published guidelines. The partial, full, and no implementation scores were 92.5%, 4.5%, and 3.0%, respectively. Full implementation was better for the low-minimal emetogenic regimens (34.8%) than the highly emetogenic regimens (6.1%). The three most frequent reasons for hampered implementation of ASCO guidelines in routine chemotherapy practice cited by centers were a lack of sensitization (26 centers; 39.4%), lack of national guidelines (12 centers; 18.2%), and lack of administrative support (10 centers; 15.2%).ConclusionAwareness regarding ASCO antiemetic guidelines is satisfactory in Indian oncology practices; however, there is a need for sensitization of oncologists toward complete implementation of these guidelines in their clinical practice.

show abstract

A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center

Cited by 9 publications

References 15 publications

A retrospective review of treatment patterns of antiemetic agents for chemotherapy-induced nausea and vomiting

A retrospective review of treatment patterns of antiemetic agents for chemotherapy-induced nausea and vomiting

Evaluation of pre-chemotherapy antiemetic prescriptions in a hospital unit

Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline

Contact Info

Product

Resources

About